vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v11i2.230vsp-137Research ArticleКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯCLINICAL OBSERVATIONSОПЫТ ПРИМЕНЕНИЯ АБАТАЦЕПТА У БОЛЬНОЙ СЕРОПОЗИТИВНЫМ ВАРИАНТОМ ИДИОПАТИЧЕСКОГО ЮВЕНИЛЬНОГО АРТРИТАEXPERIENCE OF ABATACEPT TREATMENT IN A PATIENT WITH ANTIBODY-POSITIVE IDIOPATHIC JUVENILE ARTHRITISБзароваТ. М.BzarovaT. M.alekatya@ya.ruАлексееваЕ. И.AlekseevaE. I.

Алексеева Екатерина Иосифовна, доктор медицинских наук, профессор, заведующая ревматологическим отделением Научного центра здоровья детей РАМН, декан педиатрического факультета Первого МГМУ им. И.М. Сеченова

Ekaterina Iosifovna Alexeeva, PhD, professor, Head of the Pediatric Department of I.M. Sechenov First MSMU, Head of the Rheumatologic Department of SCCH of RAMS

 

alekatya@ya.ruФетисоваА. Н.FetisovaA. N.alekatya@ya.ruКлочковаО. А.KlotchkovaO. A.alekatya@ya.ruНаучный центр здоровья детей РАМН, МоскваРоссияScientific Centre of Children Health RAMS, MoscowRussian FederationНаучный центр здоровья детей РАМН, Москва; Первый Московский государственный медицинский университет им. И.М. СеченоваРоссияScientific Centre of Children Health RAMS, Moscow; I.M. Sechenov First Moscow State Medical UniversityRussian Federation201215032012112Вопросы современной педиатрии155161Copyright © Бзарова Т.М., Алексеева Е.И., Фетисова А.Н., Клочкова О.А., 20122012Бзарова Т.М., Алексеева Е.И., Фетисова А.Н., Клочкова О.А.Bzarova T.M., Alekseeva E.I., Fetisova A.N., Klotchkova O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/137детиювенильный идиопатический артритабатацептлечениеchildrenjuvenile idiopathic arthritisabatacepttreatmentReferencesCassidy J., Petty R. eds. Texbook of paediatric rheumatology, 5th Ed. Elsevier Saunders. 2005.Cassidy J., Petty R. eds. Texbook of paediatric rheumatology, 5th Ed. Elsevier Saunders. 2005.Alekseeva E. I., Litvitskii P. F. Yuvenil'nyi revmatoidnyi artrit. Etiologiya. Patogenez. Klinika. Algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Pod obshchei red. akad. RAMN, prof. A. A. Baranova [Juvenile Rheumatoid Arthritis. Etiology. Pathogenesis. Clinical Picture. Diagnostic Procedure and Treatment. Guidekine for doctors, teachers and research scientists. Edited by academiciab of RAMS, professor A. A. Baranov]. Мoscow, 2007. pp. 325–339.Alekseeva E. I., Litvitskii P. F. Yuvenil'nyi revmatoidnyi artrit. Etiologiya. Patogenez. Klinika. Algoritmy diagnostiki i lecheniya. Rukovodstvo dlya vrachei, prepodavatelei, nauchnykh sotrudnikov. Pod obshchei red. akad. RAMN, prof. A. A. Baranova [Juvenile Rheumatoid Arthritis. Etiology. Pathogenesis. Clinical Picture. Diagnostic Procedure and Treatment. Guidekine for doctors, teachers and research scientists. Edited by academiciab of RAMS, professor A. A. Baranov]. Мoscow, 2007. pp. 325–339.Woo P., Southwood T. R., Prieur A. M. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43 (8): 1849–1857.Woo P., Southwood T. R., Prieur A. M. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43 (8): 1849–1857.Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.Nasonov E. L. Russkii meditsinskii zhurnal — Russian medical journal. 2009; 17 (3): 2–7.Nasonov E. L. Russkii meditsinskii zhurnal — Russian medical journal. 2009; 17 (3): 2–7.Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.Davies P., Zhou L., Abraham R. Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity. J. Rheumatol. 2007; 34: 280–289.Linsley P. S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.Linsley P. S., Brady W., Urnes M. et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 1991; 174 (3): 561–569.Webb L. M., Walmsley M. J., Feldmann M. Prevention and amelioration of collagen–induced arthritis by blockade of the CD28 co–stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.Webb L. M., Walmsley M. J., Feldmann M. Prevention and amelioration of collagen–induced arthritis by blockade of the CD28 co–stimulatory pathway: requirement for both B7–1 and B7–2. Eur. J. Immunol. 1996; 26: 2320–2328.Moreland L. W., Alten R., Bosch F. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose–finding, doubleblind, placebo-controlled clinical trial evaluating CTLA–4Ig and LEA29Y eighty–five days after the first infusion. Arthritis Rheum. 2002; 46: 1470–1479.Moreland L. W., Alten R., Bosch F. et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose–finding, doubleblind, placebo-controlled clinical trial evaluating CTLA–4Ig and LEA29Y eighty–five days after the first infusion. Arthritis Rheum. 2002; 46: 1470–1479.Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003; 349: 1907–1915.Kremer J. M., Westhovens R., Leon M. et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 2003; 349: 1907–1915.Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double–blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.Kremer J. M., Dougados M., Emery P. et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double–blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52: 2263–2271.Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate–resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.Kremer J. M., Genant H. K., Moreland L. W. et al. Effects of abatacept in patients with methotrexate–resistant active rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 2006; 144: 865–876.Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353: 1114–1123.Genovese M. C., Becker J. C., Schiff M. et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N. Engl. J. Med. 2005; 353: 1114–1123.Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009; 68 (11): 1708–1714.Schiff M. H., Pritchard C., Huffstutter J. E. et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-TNF therapy or were directly switched to abatacept: the ARRIVE trial. Ann. Rheum. Dis. 2009; 68 (11): 1708–1714.Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi centre, randomised, double-blind, placebo–controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008; 67: 1096–1103.Schiff M., Keiserman M., Codding C. et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi centre, randomised, double-blind, placebo–controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann. Rheum. Dis. 2008; 67: 1096–1103.Kremer J. M., Genant H. K., Moreland L. W. et al. Results of a two–year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58: 953–963.Kremer J. M., Genant H. K., Moreland L. W. et al. Results of a two–year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 2008; 58: 953–963.Genant H. K., Peterfy C. G., Westhovens R. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long–term extension of the AIM trial. Ann. Rheum. Dis. 2008; 67: 1084–1089.Genant H. K., Peterfy C. G., Westhovens R. et al. Abatacept inhibits structural damage progression in rheumatoid arthritis: results from the long–term extension of the AIM trial. Ann. Rheum. Dis. 2008; 67: 1084–1089.Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease–modifying antirheumatic drugs: a one–year randomized, placebo–controlled study. Arthritis Rheum. 2006; 54: 2807–2816.Weinblatt M., Combe B., Covucci A. et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease–modifying antirheumatic drugs: a one–year randomized, placebo–controlled study. Arthritis Rheum. 2006; 54: 2807–2816.Weinblatt M., Schiff M., Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 2007; 66: 228–234.Weinblatt M., Schiff M., Goldman A. et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. Ann. Rheum. Dis. 2007; 66: 228–234.Westhovens R., Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009; 68 (12): 1870–1877.Westhovens R., Robles M., Ximenes A. D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann. Rheum. Dis. 2009; 68 (12): 1870–1877.Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [OP-0130]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 89.Emery P., Durez P., Dougados M. et al. Efficacy of abatacept in delaying the development of rheumatoid arthritis (RA) in adult patients with undifferentiated inflammatory arthritis at high risk of developing RA [OP-0130]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 89.Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacepttreated RA patients background methotrexate [FRI0171]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 341.Westhovens R., Kremer J., Moreland L. et al. Durable impact on disease activity and consistent safety through 5 years in abatacepttreated RA patients background methotrexate [FRI0171]. Ann. Rheum. Dis. 2008; 67 (Suppl. II): 341.Weisman M. H., Durez P., Hallegua D. et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 2006; 33: 2162–2166.Weisman M. H., Durez P., Hallegua D. et al. Reduction of inflammatory biomarker response by abatacept in the treatment of rheumatoid arthritis. J. Rheumatol. 2006; 33: 2162–2166.Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Eheumatol. 2007; 25 (Suppl. 46): 46–56.Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin. Exp. Eheumatol. 2007; 25 (Suppl. 46): 46–56.Ruperto N., Lovell D. J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.Ruperto N., Lovell D. J., Quartier P. et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebocontrolled withdrawal trial. Lancet. 2008; 372 (9636): 383–391.

The authors declare that there are no conflicts of interest present.